BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 137 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $611,000 | +44.8% | 60,000 | +6.0% | 0.02% | +57.1% |
Q4 2020 | $422,000 | +62.3% | 56,600 | -25.1% | 0.01% | +55.6% |
Q3 2020 | $260,000 | -31.9% | 75,600 | -5.7% | 0.01% | -10.0% |
Q2 2020 | $382,000 | +126.0% | 80,200 | -5.3% | 0.01% | +100.0% |
Q1 2020 | $169,000 | -70.5% | 84,700 | -43.9% | 0.01% | -61.5% |
Q2 2019 | $572,000 | -70.1% | 150,998 | -35.7% | 0.01% | -66.7% |
Q1 2019 | $1,913,000 | +2.5% | 234,898 | +1.6% | 0.04% | -2.5% |
Q4 2018 | $1,866,000 | +1.0% | 231,198 | -4.5% | 0.04% | +21.2% |
Q3 2018 | $1,847,000 | +29.8% | 241,998 | -2.5% | 0.03% | +32.0% |
Q2 2018 | $1,423,000 | +1.0% | 248,198 | -15.9% | 0.02% | +4.2% |
Q1 2018 | $1,409,000 | +3.4% | 295,166 | +6.3% | 0.02% | +4.3% |
Q4 2017 | $1,363,000 | +247.7% | 277,567 | +271.6% | 0.02% | +155.6% |
Q3 2017 | $392,000 | +166.7% | 74,700 | +398.0% | 0.01% | +80.0% |
Q3 2014 | $147,000 | +104.2% | 15,000 | +51.5% | 0.01% | +66.7% |
Q3 2013 | $72,000 | – | 9,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |